600566 Hubei Jumpcan Pharmaceutical
- 30.68
- -0.06-0.20%
Hubei Jumpcan Pharmaceutical News
Jichuan Pharmaceutical (600566): Performance is in line with expectations, optimistic about next year's performance flexibility
Jichuan Pharmaceutical (600566): Improved month-on-month performance, and short-term growth of core varieties is expected to improve
Jichuan Pharmaceutical (600566): Short-term performance is under pressure and will not change the long-term positive trend
Jichuan Pharmaceutical (600566): Short-term fluctuations in performance, BD is expected to empower long-term development
Jichuan Pharmaceutical (600566): Buyback shows long-term business confidence BD continues to advance
Jichuan Pharmaceutical (600566): Excellent 24Q1 performance, steady core product performance, and employee stock ownership plans show confidence
Jichuan Pharmaceutical (600566): Strong sales in core categories, 24Q1 profit growth exceeded expectations
Jichuan Pharmaceutical (600566): Outstanding sales of core categories, gradual increase in profitability
Jichuan Pharmaceutical (600566): The 24Q1 profit growth rate exceeded expectations, and the employee stock ownership plan showed long-term business confidence
Zhongtai Securities released a research report on April 21 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) Q1 performance surpassed expectations, and the return home achieved 25% growt
Jichuan Pharmaceutical (600566): The profit growth rate continues to exceed expectations, and the sales platform has significant advantages
Open Source Securities released a research report on April 20 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the rotation and handover of growth drivers, and pediatrics has become the
Jichuan Pharmaceutical (600566): Fee control guarantees high profit growth and improved operating capacity
Jichuan Pharmaceutical (600566) Company's First Coverage Report: Pediatric Business Accelerates Sailing, High Quality BD Empowers Long-term Development
Jichuan Pharmaceutical (600566): Performance exceeds expectations, profitability improved significantly
Dongwu Securities released a research report on April 17 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the accelerated release of Q4 profits, which are expected to maintain high prof
Jichuan Pharmaceutical (600566): Expenses were effectively controlled during the period, and profit margins were further increased
Jichuan Pharmaceutical (600566) 2023 Annual Report Review Report: Rapid growth in performance, steady progress in BD innovation and transformation
Southwest Securities released a research report on April 11 stating that it gave Jichuan Pharmaceutical (600566.SH) a purchase rating. The main reasons for the rating include: 1) the profit growth rate in 2023 exceeded expectations, and profitability was
Jichuan Pharmaceutical (600566): Fee control guarantees high profit growth, BD is expected to contribute to new volume
Analysis
Price Target
No Data
No Data